By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Basilea Pharmaceutica 

Grenzacherstrasse 487

Basel    CH-4005  Switzerland
Phone: 41-61-6061-111 Fax: 41-61-6061-112


Company News
GlaxoSmithKline (GSK) Kills U.S. Part of Eczema Treatment Deal With Basilea (BSLN.SW) 1/22/2016 5:57:43 AM
Basilea Pharmaceutica (BSLN.SW) Reports Start Of First-In-Human Phase I Oncology Study With Oral Panraf Kinase Inhibitor 5/4/2015 2:47:29 PM
Basilea Pharmaceutica (BSLN.SW) Shareholders Approve All Resolutions Proposed By The Board Of Directors At The Ordinary General Meeting Of Shareholders 4/29/2015 10:52:52 AM
Basilea Pharmaceutica (BSLN.SW) Reports U.S. FDA Approval Of Isavuconazole For The Treatment Of Invasive Aspergillosis And Invasive Mucormycosis 3/9/2015 7:25:46 AM
Basilea Pharmaceutica (BSLN.SW) Announces Launch Of Antibiotic Zevtera(R) (Ceftobiprole Medocaril) In Germany 12/5/2014 9:37:37 AM
Basilea Pharmaceutica (BSLN.SW) Reports Protocol Amendment Resulting In Earlier Completion Of Isavuconazole Phase 3 Invasive Candidiasis Study 10/16/2014 7:18:27 AM
Basilea Pharmaceutica (BSLN.SW)'s Partner Astellas Pharma Inc. (ALPMY) Receives Notification From FDA Of Acceptance Of Filing Of Isavuconazole NDA For The Treatment Of Invasive Aspergillosis And Invasive Mucormycosis 9/8/2014 7:17:05 AM
Basilea Pharmaceutica (BSLN.SW) To Launch Zevtera®/Mabelio®) (ceftobiprole medocaril) In Europe Through A Commercial Services Provider 7/21/2014 1:38:10 PM
Basilea Pharmaceutica (BSLN.SW) Isavuconazole European Marketing Authorization Application For The Treatment Of Invasive Mold Infections 7/17/2014 6:09:09 AM
Basilea Pharmaceutica (BSLN.SW) Reports That Isavuconazole Receives Orphan Drug Designations In Europe For The Treatment Of Invasive Mold Infections 7/14/2014 5:57:05 AM